The Function of RAS Mutation in Cancer and Advances in its Drug Research
Authors:
- 5 August 2019
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 25 (10) , 1105-1114
Abstract
RAS (H-ras, K-ras, and N-ras), as the second largest mutated gene driver in various human cancers, has long been a vital research target for cancer. Its function is to transform the extracellular environment into a cascade of intracellular signal transduction. RAS mutant protein regulates tumor cell proliferation, apoptosis, metabolism and angiogenesis through downstream MAPK, PI3K and other signaling pathways. In KRAS or other RAS-driven cancers, current treatments include direct inhibitors and upstream/downstream signaling pathway inhibitors. However, the research on these inhibitors has been largely restricted due to their escape inhibition and off-target toxicity. In this paper, we started with the role of normal and mutant RAS genes in cancer, elucidated the relevant RAS regulating pathways, and highlighted the important research advancements in RAS inhibitor research. We concluded that for the crosstalk between RAS pathways, the effect of single regulation may be limited, and the multi-target drug combined compensation mechanism is becoming a research hotspot.Keywords
Funding Information
- China Pharmaceutical University “Double First-Class” Construction Technology Innovation Team (CPU2018GY23)
- National Science and Technology Major Project of the Ministry of Science and Technology of China (2016ZX09101031)
This publication has 73 references indexed in Scilit:
- Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activityProceedings of the National Academy of Sciences, 2012
- RAS oncogenes: weaving a tumorigenic webNature Reviews Cancer, 2011
- Oncogenic K‐Ras decouples glucose and glutamine metabolism to support cancer cell growthMolecular Systems Biology, 2011
- Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesisGenes & Development, 2011
- Regulation of cancer cell metabolismNature Reviews Cancer, 2011
- FOXO3a Regulates Glycolysis via Transcriptional Control of Tumor Suppressor TSC1Journal of Biological Chemistry, 2010
- Genetic analysis of Ras signalling pathways in cell proliferation, migration and survivalThe EMBO Journal, 2010
- Smad3 Protein Levels Are Modulated by Ras Activity and during the Cell Cycle to Dictate Transforming Growth Factor-β ResponsesJournal of Biological Chemistry, 2010
- H‐Ras increases urokinase expression and cell invasion in genetically modified human astrocytes through Ras/Raf/MEK signaling pathwayGlia, 2008
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003